CAMBRIDGE, Mass., Jan. 3, 2018 /PRNewswire/ -- TCR2 Therapeutics, an immuno-oncology company pioneering a novel class of T cell therapies for solid tumors, announced today that its Chief Executive Officer, Garry E. Menzel, Ph.D., will present a corporate overview at the 36th Annual J.P. Morgan Healthcare Conference.
The presentation will take place on Wednesday, January 10, 2018 at 3PM PT (6PM ET) in the Westin St. Francis Hotel, San Francisco.
About TCR2 TherapeuticsTCR2 Therapeutics is an immuno-oncology company that has pioneered a novel class of T cell therapies for solid tumors that utilize the full signaling power of complete T cell receptors (TCR). TCR2 has developed a unique proprietary TRuC™ platform which can reprogram the natural TCR complex to elicit rapid killing of cancer cells with persistence and low cytokine release. The company has demonstrated superior activity against several tumor targets in preclinical models compared to CAR T cells and will advance its lead program TC-210 into the clinic in 2018. TCR2 was founded in 2015 by Dr. Patrick Baeuerle and backed with a $44.5M Series A financing led by MPM Capital and F2 Ventures. It has since assembled a world-class team of immunotherapy experts and entrepreneurs located in the heart of Kendall Square in Cambridge, MA. For more information, please visit www.tcr2.com.
Advertisement
The presentation will take place on Wednesday, January 10, 2018 at 3PM PT (6PM ET) in the Westin St. Francis Hotel, San Francisco.
Advertisement
About TCR2 TherapeuticsTCR2 Therapeutics is an immuno-oncology company that has pioneered a novel class of T cell therapies for solid tumors that utilize the full signaling power of complete T cell receptors (TCR). TCR2 has developed a unique proprietary TRuC™ platform which can reprogram the natural TCR complex to elicit rapid killing of cancer cells with persistence and low cytokine release. The company has demonstrated superior activity against several tumor targets in preclinical models compared to CAR T cells and will advance its lead program TC-210 into the clinic in 2018. TCR2 was founded in 2015 by Dr. Patrick Baeuerle and backed with a $44.5M Series A financing led by MPM Capital and F2 Ventures. It has since assembled a world-class team of immunotherapy experts and entrepreneurs located in the heart of Kendall Square in Cambridge, MA. For more information, please visit www.tcr2.com.
View original content:http://www.prnewswire.com/news-releases/tcr2-therapeutics-to-present-at-the-36th-annual-jp-morgan-healthcare-conference-300577202.html
SOURCE TCR2 Therapeutics
